About 10 to 15% of breast cancers are classified as triple negative because they lack receptors for estrogen, progesterone, and HER2. They can be harder to treat because they don’t respond to drugs that target estrogen, progesterone, or HER2 receptors. Women with triple-negative breast cancer are mainly treated with chemotherapy or take part in clinical trials. Join us for this educational webinar that will cover the following topics pertaining to Triple Negative Breast Cancer (TNBC): Recent changes in standard of care therapy; The use of chemotherapy in patients who are found to have residual breast cancer; Post neoadjuvant therapy and the use of immunotherapy, both in the early stage and metastatic settings; Some of the novel treatment strategies that are under investigation for the treatment of patients with metastatic TNBC. SPEAKER: Ayca Gucalp, MD, Assistant Attending, Breast Medicine Service, Memorial Sloan Kettering Cancer Center; Board Certified in Internal Medicine and Medical Oncology.Dr. Gucalp is a medical oncologist with a clinical practice dedicated exclusively to the care of patients diagnosed with breast cancer. Her research activities are focused on the development of novel therapeutic strategies for the treatment of triple negative breast cancer .